$3.42
2.01% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Xeris Pharmaceuticals Inc Stock price

$3.42
+0.34 11.04% 1M
+1.31 62.09% 6M
+1.07 45.53% YTD
+1.33 63.64% 1Y
+0.83 32.05% 3Y
-4.53 56.98% 5Y
-16.80 83.09% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
-0.07 2.01%
ISIN
US98422L1070
Symbol
XERS
Sector
Industry

Key metrics

Market capitalization $509.86m
Enterprise Value $711.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.80
P/S ratio (TTM) P/S ratio 2.72
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 22.72%
Revenue (TTM) Revenue $187.36m
EBIT (operating result TTM) EBIT $-45.17m
Free Cash Flow (TTM) Free Cash Flow $-33.45m
Cash position $69.40m
EPS (TTM) EPS $-0.44
P/E forward negative
P/S forward 2.55
EV/Sales forward 3.56
Short interest 6.81%
Show more

Is Xeris Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Xeris Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Xeris Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Xeris Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
187 187
23% 23%
100%
- Direct Costs 46 46
20% 20%
24%
142 142
24% 24%
76%
- Selling and Administrative Expenses 148 148
14% 14%
79%
- Research and Development Expense 26 26
24% 24%
14%
-32 -32
10% 10%
-17%
- Depreciation and Amortization 13 13
5% 5%
7%
EBIT (Operating Income) EBIT -45 -45
8% 8%
-24%
Net Profit -63 -63
2% 2%
-34%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Pharmaceuticals Inc Stock News

Neutral
Business Wire
28 days ago
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare...
Neutral
Seeking Alpha
about 2 months ago
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President of Investor Relations, Corporate Communications Conference Call Participants Chase Knickerbocker - Craig-Hallam Leland Gershell - Oppenheimer. Oren Livnat ...
Neutral
Business Wire
about 2 months ago
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2024. “We are proud to report our record-breaking quart...
More Xeris Pharmaceuticals Inc News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 377
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today